Toggle Nav
Close
  • Menu
  • Setting

LXR-623

Catalog No.
B1264
Liver X-receptor agonist
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$71.00
In stock
5mg
$68.00
In stock
10mg
$83.00
In stock
50mg
$295.00
In stock
100mg
$479.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

LXR-623 is an agonist of liver X-receptor with IC50 values of 179nM and 24nM for LXR-α and LXR-β, respectively [1].

LXR-623 is a partial agonist of LXR which regulates the transcription of genes involved in cellular cholesterol homeostasis. As the LXR agonist, LXR-623 is used to enhance reverse cholesterol transport through up-regulating cholesterol transporters. To rodents, orally dosed LXR-623 increases the transcription level of ABCA1 and ABCG1 in peripheral blood cells. To human, LXR-623 also significantly increases ABCA1 and ABCG1 both in PBMC cells and in T- and B-cells. In addition, in mouse model of atherosclerosis, LXR-623 is found to up-regulate intestinal ABCG5 and ABCG8. In cynomolgus monkeys, LXR-623 up-regulates ABCA1 and ABCG1 in whole blood. Besides that, LXR-623 is proposed to be used in treatment of Alzheimer’s disease since it can lower the level of amyloid-βin brain [1, 2].

References:
[1] Katz A, Udata C, Ott E, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants. The Journal of Clinical Pharmacology, 2009, 49(6): 643-649.
[2] DiBlasio-Smith E A, Arai M, Quinet E M, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med, 2008, 6: 59.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt422.78
Cas No.875787-07-8
FormulaC21H12ClF5N2
Solubility≥19.4mg/mL in DMSO
Chemical Name2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)indazole
SDFDownload SDF
Canonical SMILESC1=CC2=C(N(N=C2C(=C1)C(F)(F)F)CC3=C(C=C(C=C3)F)Cl)C4=CC=C(C=C4)F
Shipping ConditionEvaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.
General tipsFor obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Protocol

Cell experiment [1]:

Cell lines

Human peripheral blood mononuclear cells

Preparation method

The solubility of this compound in DMSO is >19.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

2 μM, 18 hours

Applications

LXR-623 (2 μM for either 24 or 48 hours) treatment significantly upregulated mRNA for ABCA1, ABCG1, and PLTP in human PBMC. In PBMC, monocytes, T cells, and B cells, treatment with 2 μM LXR-623 for 18 hours resulted in approximately 6 fold induction of ABCA1 mRNA levels.

Animal experiment [1]:

Animal models

C57/Bl6 mice, Normal male rats

Dosage form

Oral administration, 50 mg/kg, 30 mg/kg

Application

Oral administration of LXR-623 (30 mg/kg) induced ABCA1 and ABCG1 gene expression in rodent peripheral blood cells in vivo.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. DiBlasio-Smith E A, Arai M, Quinet E M, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells[J]. Journal of translational medicine, 2008, 6(1): 59.

Quality Control

Chemical structure

LXR-623

Related Biological Data

LXR-623

Related Biological Data

LXR-623